Drug name - Tazverik
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| CN107311921B | EPIZYME INC | Aryl Or Heteroaryl Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| CN104080769A | EPIZYME INC | Aryl Or Heteroaryl Substituted Benzene Compound |
Apr, 2032
(9 years from now) | |
| CN104080769B | EPIZYME INC | Aryl Or Heteroaryl Substituted Benzene Compound |
Apr, 2032
(9 years from now) | |
| CN107311921A | EPIZYME INC | Aryl Or Heteroaryl Substituted Benzene Compound |
Apr, 2032
(9 years from now) | |
| CN108358899A | EPIZYME INC | Human Salt Form Transmethylase Ezh2 Inhibitor Of |
Apr, 2033
(10 years from now) | |
| CN104603130A | EPIZYME INC | Salt Forms Of Human Histone Methyltransferase Ezh2 Inhibitor |
Apr, 2033
(10 years from now) | |
| CN104603130B | EPIZYME INC | A Salt Form Of Histone Methyltransferase Ezh2 Inhibitor |
Apr, 2033
(10 years from now) | |
| CN108358899B | EPIZYME INC | Salt Form Of Human Histone Methyltransferase Ezh2 Inhibitor |
Apr, 2033
(10 years from now) | |
| IN337354B | EPIZYME INC | Aryl-Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP2697199A1 | EPIZYME INC | Aryl-Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP3150580B1 | EPIZYME INC | Aryl- Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP3486234B1 | EPIZYME INC | Aryl- Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP3486234A1 | EPIZYME INC | Aryl- Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP2697199B1 | EPIZYME INC | Aryl-Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP3150580A1 | EPIZYME INC | Aryl- Or Heteroaryl-Substituted Benzene Compounds |
Apr, 2032
(9 years from now) | |
| EP3184523B1 | EPIZYME INC | N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System |
Apr, 2033
(10 years from now) | |
| EP2836491A4 | EPIZYME INC | Salt Form Of A Human Hi Stone Methyltransf Erase Ezh2 Inhibitor |
Apr, 2033
(10 years from now) | |
| EP2836491B1 | EPIZYME INC | Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor |
Apr, 2033
(10 years from now) | |
| EP2836491A1 | EPIZYME INC | Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor |
Apr, 2033
(10 years from now) | |
| EP3184523A1 | EPIZYME INC | N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System |
Apr, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
| US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
| US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(8 years from now) | |
| US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
| US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
| US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(8 years from now) | |
| US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(9 years from now) | |
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(11 years from now) | |
| US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(13 years from now) | |
| US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(13 years from now) | |
| US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(13 years from now) | |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.